is a pharmaceutical
company focused on
compounds in the
endocrine and metabolic
Our most advanced product, ospemifene, received FDA approval in February 2013 for the treatment of moderate to severe
dyspareunia (painful sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
It was launched in May 2013 by our partner Shionogi Inc. under the trade name
For more information see www.Osphena.com
QuatRx Pharmaceuticals has now divested all other clinical and pre-clinical programs in its portfolio to
Forendo Pharma, based in Turku, Finland.
For more information see www.Forendo.com